Incyte JPM 2025

Industry and Company Overview * Industry: Biotechnology and pharmaceuticals * Company: Incyte Corporation * Focus: Drug development and commercialization Key Financial Highlights * 2024 Revenue: $3.1 billion (up 14$2 billion in cash and no debt Pipeline and Pipeline Programs * Niktimvo™: Approved for 3L+ cGVHD, with potential for label expansion into 1L cGVHD * Retifanlimab: sBLA submitted for SCAC, with potential to become the new standard of care * Tafasitamab: sBLA submitted for r/r FL, with potential for label expansion into 1L DLBCL * Ruxolitinib Cream: sNDA submitted for pediatric AD, with potential for label expansion into PN and HS * Povorcitinib: Phase 3 studies in HS, vitiligo, and prurigo nodularis, with potential for best-in-class efficacy * mCALR: Proof-of-concept data expected in 2025, with potential to eradicate the malignant clone in MF and ET patients * CDK2 Inhibitor: Phase 1 data in ovarian cancer, with potential for pivotal trial initiation in 2025 High Impact Pipeline Programs * Povorcitinib: Addressing significant unmet needs in HS, vitiligo, and prurigo nodularis * mCALR: Targeting mutated calreticulin in MF and ET patients * CDK2 Inhibitor: Targeting cyclin-dependent kinases in ovarian cancer Key Catalysts for 2025 * Ruxolitinib Cream approval for pediatric AD * Povorcitinib data in HS, vitiligo, and prurigo nodularis * mCALR proof-of-concept data * CDK2 inhibitor pivotal trial initiation * Potential high impact launches by 2030 Conclusion Incyte is well-positioned for growth in 2025 and beyond, with a strong pipeline of innovative drugs addressing significant unmet needs in various indications. The company's focus on novel biology and high patient impact positions it for long-term success.